Oculis
Develops investigational therapies for neuro-ophthalmology and dry eye disease.
$12.21
After-hours close−0.01 (−0.08%)
At close$12.22(−1.69%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.48 | — | — |
| Aug 2026 | −$0.48 | −$0.20 | +58.3% |
| May 2026 | −$0.49 | −$0.63 | −28.6% |
| Mar 2026 | −$0.48 | −$0.51 | −6.7% |
| Nov 2025 | −$0.50 | −$0.40 | +20.0% |
The latest year is open to everyone — the 16 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| Mar 2023 | |||
| Mar 2023 | |||
| Sep 2022 | |||
| Jun 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$0.48 | — | — | $268.5K | — | — |
| Aug 6, 2026 | −$0.48 | −$0.20 | +58.3% | $216.8K | $371.1K | +71.2% |
| May 11, 2026 | −$0.49 | −$0.63 | −28.6% | $253.8K | $250.3K | −1.4% |
| Mar 3, 2026 | −$0.48 | −$0.51 | −6.7% | $142.9K | $518.4K | +262.8% |
| Nov 10, 2025 | −$0.50 | −$0.40 | +20.0% | $136.9K | $305.5K | +123.2% |
The latest year is open to everyone — the 16 quarters behind it read with an account. Sign in | ||||||
| Aug 21, 2025 | ||||||
| May 8, 2025 | ||||||
| Mar 11, 2025 | ||||||
| Nov 7, 2024 | ||||||
| Aug 27, 2024 | ||||||
| May 8, 2024 | ||||||
| Mar 18, 2024 | ||||||
| Nov 15, 2023 | ||||||
| Aug 29, 2023 | ||||||
| Mar 31, 2023 | ||||||
| Mar 28, 2023 | ||||||
| Sep 30, 2022 | ||||||
| Jun 30, 2022 | ||||||
| Mar 31, 2022 | ||||||
| Dec 31, 2021 | ||||||
| Sep 30, 2021 | ||||||